N. Tsai

Real‐world effectiveness for 12 weeks of ledipasvir–sofosbuvir for genotype 1 hepatitis C: the Trio Health study

Elliot B. Tapper, Bruce R. Bacon, Michael P. Curry et al. · Journal of Viral Hepatitis · 2016 · 75 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Disparate access to treatment regimens in chronic hepatitis <scp>C</scp> patients: data from the <scp>TRIO</scp> network

Zobair M. Younossi, Bruce R. Bacon, Douglas T. Dieterich et al. · Journal of Viral Hepatitis · 2016 · 61 citations

Pharmacy, Pharmacoeconomics, Pharmacotherapy +17

Effect of iron depletion on long-term response to interferon-alpha in patients with chronic hepatitis C who previously did not respond to interferon therapy.

N. Tsai, E. Zuckerman, Steven Hb Han et al. · PubMed · 1997 · 56 citations

Pharmacy, Immunology, Pharmacotherapy +17

P0775 : Final evaluation of 955 HCV patients treated with 12 week regimens containing sofosbuvir +/- simeprevir in the trio network: Academic and community treatment of a real-world, heterogeneous population

Doug Dieterich, Bruce R. Bacon, Steven L. Flamm et al. · Journal of Hepatology · 2015 · 43 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +14

Effectiveness of 8‐ or 12‐weeks of ledipasvir and sofosbuvir in real‐world treatment‐naïve, genotype 1 hepatitis C infected patients

Michael P. Curry, Elliot B. Tapper, Bruce R. Bacon et al. · Alimentary Pharmacology & Therapeutics · 2017 · 38 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +15